Correction: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.

Autor: Hao, Jiaojiao, Fan, Wenhua, Li, Yizhuo, Tang, Ranran, Tian, Chunfang, Yang, Qian, Zhu, Tianhua, Diao, Chaoliang, Hu, Sheng, Chen, Manyu, Guo, Ping, Long, Qian, Zhang, Changlin, Qin, Ge, Yu, Wendan, Chen, Miao, Li, Liren, Qin, Lijun, Wang, Jingshu, Zhang, Xiuping
Předmět:
Zdroj: Journal of Experimental & Clinical Cancer Research (17569966); 6/26/2024, Vol. 43 Issue 1, p1-5, 5p
Abstrakt: This document is a correction notice for an article titled "Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits." The authors identified errors in Figure 3c and Figure 5e of the original article. The corrected figures show the effects of melatonin and vemurafenib on apoptosis and cancer stem cell traits in melanoma cells. The study suggests that the combination of melatonin and vemurafenib may be effective in treating melanoma by inhibiting specific signaling pathways. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje